Skip to main content

Table 4 Intraprocedural characteristics (n = 780)

From: Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants

 

Group A

Bridging

(n = 111)

Group B

VKA

(n = 318)

Group C

DOAC

(n = 351)

p-value

A-B

p-value

A-C

p-value

B-C

Procedural time (min)

241.5 ± 94.6

225.4 ± 83.4

185.1 ± 74.7

0.092

< 0.001

< 0.001

Heparin dosage (IU)

9176.0 ± 3774.1

7994.8 ± 3120.3

10457.3 ± 4293.5

0.003

0.005

< 0.001

Heparin dosage (IU/h)

2497.7 ± 1183.4

2335.1 ± 1091.3

3666.1 ± 1554.8

0.187

< 0.001

< 0.001

Heparin dosage (IU/h/kg)

29.4 ± 14.7

27.8 ± 19.9

44.00 ± 18.8

0.33

< 0.001

< 0.001

Mean ACT (seconds)

337.3 ± 64.3

335.6 ± 45.8

315.7 ± 44.1

0.803

0.001

< 0.001

Max ACT (seconds)

363.7 ± 48.5

383.8 ± 30.4

370.7 ± 32.8

< 0.001

0.163

< 0.001

Time to ACT> 300 (seconds)

70.1 ± 66.7

36.6 ± 34.5

26.8 ± 17.2

< 0.001

< 0.001

< 0.001

  1. Legend: values are means with standard deviations; ACT activated clotting time, Bridging interrupted vitamin-K-antagonist, DOAC uninterrupted non-vitamin-K-anticoagulants, h hour, IU international units, kg kilogram, max maximal, min minutes
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us